|
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. |
|
|
Research Funding - Novartis (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - Caremission; Medelis |
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MedImmune (Inst); Merck Serono (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Sirtex Medical (Inst) |
|
|
Consulting or Advisory Role - Nordic Bioscience |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Research Funding - AstraZeneca (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |